94 results
424B3
RGBP
Regen BioPharma Inc
29 Apr 24
Prospectus supplement
4:08pm
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS
8-K
EX-10.1
RGBP
Regen BioPharma Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:07pm
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS WHEREOF, the parties have
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application … States federal tax credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes
424B3
RGBP
Regen BioPharma Inc
2 Oct 23
Prospectus supplement
1:42pm
% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application of HemaXellerate qualifies for Orphan
8-K
EX-10.1
8riqy8p6f c6h
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.4
8ltblsc7vr2zrowuz
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.3
0cbgeb
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
6kgcazhyoag8pkzn
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
j7h9 chkd
15 May 23
Prospectus supplement
10:25am